PDCD1 and pituitary adenocarcinoma: In 2018, Lin et al. successfully treated a first case of aggressive ACTH-secreting pituitary carcinoma with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) combination immunotherapy (5).